Myopia is a growing public health concern, with increasing prevalence among children. Effective management strategies are essential to prevent excessive axial elongation, which can lead to serious ocular complications. Recent innovations in spectacle lens design, such as DIMS, are being explored for myopia control.
Data Highlights
Lens Type
Mean Axial Elongation (12 months)
Percentage of Eyes in Physiological Growth Zone
Single-Vision Spectacles
0.346 mm
22%
MiYOSMART
0.20 mm
57%
MiYOSMART iQ
0.075 mm
82%
Key Findings
Axial length is a critical measure in myopia management, providing insight into structural risk.
DIMS lenses have shown efficacy in reducing axial elongation compared to standard lenses.
In a study, DIMS lenses resulted in a mean axial elongation of 0.075 mm over 12 months, compared to 0.346 mm with single-vision spectacles.
22% of single-vision eyes reached the physiological growth zone, while 82% of MiYOSMART iQ eyes did.
H.A.L.T. MAX demonstrated a cumulative axial elongation of 0.121 mm.
Clinical Implications
Clinicians should consider the use of DIMS lenses as part of a comprehensive myopia management strategy. Monitoring axial length changes can provide valuable information on treatment efficacy and guide further interventions.
Conclusion
The advancements in myopia management, particularly with DIMS lenses, represent a significant step forward in controlling axial elongation and improving patient outcomes.
